Medicine (RMH) - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 4 of 4
  • Item
    Thumbnail Image
    Metabolic patterns and seizure outcomes following anterior temporal lobectomy
    Cahill, V ; Sinclair, B ; Malpas, CB ; McIntosh, AM ; Chen, Z ; Vivash, LE ; O'Shea, MF ; Wilson, SJ ; Desmond, PM ; Berlangieri, SU ; Hicks, RJ ; Rowe, CC ; Morokoff, AP ; King, JA ; Fabinyi, GC ; Kaye, AH ; Kwan, P ; Berkovic, SF ; O'Brien, TJ (WILEY, 2019-02)
    OBJECTIVE: We investigated the relationship between the interictal metabolic patterns, the extent of resection of 18 F-fluorodeoxyglucose positron emission tomography (18 FDG-PET) hypometabolism, and seizure outcomes in patients with unilateral drug-resistant mesial temporal lobe epilepsy (MTLE) following anterior temporal lobe (TL) resection. METHODS: Eighty-two patients with hippocampal sclerosis or normal magnetic resonance imaging (MRI) findings, concordant 18 FDG-PET hypometabolism, and at least 2 years of postoperative follow-up were included in this 2-center study. The hypometabolic regions in each patient were identified with reference to 20 healthy controls (p < 0.005). The resected TL volume and the volume of resected TL PET hypometabolism (TLH) were calculated from the pre- and postoperative MRI scans coregistered with interictal 18 FDG-PET. RESULTS: Striking differences in metabolic patterns were observed depending on the lateralization of the epileptogenic TL. The extent of the ipsilateral TLH was significantly greater in left MTLE patients (p < 0.001), whereas right MTLE patients had significantly higher rates of contralateral (CTL) TLH (p = 0.016). In right MTLE patients, CTL hypometabolism was the strongest predictor of an unfavorable seizure outcome, associated with a 5-fold increase in the likelihood of seizure recurrence (odds ratio [OR] = 4.90, 95% confidence interval [CI] = 1.07-22.39, p = 0.04). In left MTLE patients, greater extent of resection of ipsilateral TLH was associated with lower rates of seizure recurrence (p = 0.004) in univariate analysis; however, its predictive value did not reach statistical significance (OR = 0.96, 95% CI = 0.90-1.02, p = 0.19). INTERPRETATION: The difference in metabolic patterns depending on the lateralization of MTLE may represent distinct epileptic networks in patients with right versus left MTLE, and can guide preoperative counseling and surgical planning. Ann Neurol 2019; 1-10 ANN NEUROL 2019;85:241-250.
  • Item
    Thumbnail Image
    Polygenic burden in focal and generalized epilepsies
    Leu, C ; Stevelink, R ; Smith, AW ; Goleva, SB ; Kanai, M ; Ferguson, L ; Campbell, C ; Kamatani, Y ; Okada, Y ; Sisodiya, SM ; Cavalleri, GL ; Koeleman, BPC ; Lerche, H ; Jehi, L ; Davis, LK ; Najm, IM ; Palotie, A ; Daly, MJ ; Busch, RM ; Lal, D (OXFORD UNIV PRESS, 2019-11)
    Rare genetic variants can cause epilepsy, and genetic testing has been widely adopted for severe, paediatric-onset epilepsies. The phenotypic consequences of common genetic risk burden for epilepsies and their potential future clinical applications have not yet been determined. Using polygenic risk scores (PRS) from a European-ancestry genome-wide association study in generalized and focal epilepsy, we quantified common genetic burden in patients with generalized epilepsy (GE-PRS) or focal epilepsy (FE-PRS) from two independent non-Finnish European cohorts (Epi25 Consortium, n = 5705; Cleveland Clinic Epilepsy Center, n = 620; both compared to 20 435 controls). One Finnish-ancestry population isolate (Finnish-ancestry Epi25, n = 449; compared to 1559 controls), two European-ancestry biobanks (UK Biobank, n = 383 656; Vanderbilt biorepository, n = 49 494), and one Japanese-ancestry biobank (BioBank Japan, n = 168 680) were used for additional replications. Across 8386 patients with epilepsy and 622 212 population controls, we found and replicated significantly higher GE-PRS in patients with generalized epilepsy of European-ancestry compared to patients with focal epilepsy (Epi25: P = 1.64×10-15; Cleveland: P = 2.85×10-4; Finnish-ancestry Epi25: P = 1.80×10-4) or population controls (Epi25: P = 2.35×10-70; Cleveland: P = 1.43×10-7; Finnish-ancestry Epi25: P = 3.11×10-4; UK Biobank and Vanderbilt biorepository meta-analysis: P = 7.99×10-4). FE-PRS were significantly higher in patients with focal epilepsy compared to controls in the non-Finnish, non-biobank cohorts (Epi25: P = 5.74×10-19; Cleveland: P = 1.69×10-6). European ancestry-derived PRS did not predict generalized epilepsy or focal epilepsy in Japanese-ancestry individuals. Finally, we observed a significant 4.6-fold and a 4.5-fold enrichment of patients with generalized epilepsy compared to controls in the top 0.5% highest GE-PRS of the two non-Finnish European cohorts (Epi25: P = 2.60×10-15; Cleveland: P = 1.39×10-2). We conclude that common variant risk associated with epilepsy is significantly enriched in multiple cohorts of patients with epilepsy compared to controls-in particular for generalized epilepsy. As sample sizes and PRS accuracy continue to increase with further common variant discovery, PRS could complement established clinical biomarkers and augment genetic testing for patient classification, comorbidity research, and potentially targeted treatment.
  • Item
    Thumbnail Image
    Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies
    Abou-Khalil, B ; Auce, P ; Avbersek, A ; Bahlo, M ; Balding, DJ ; Bast, T ; Baum, L ; Becker, AJ ; Becker, F ; Berghuis, B ; Berkovic, SF ; Boysen, KE ; Bradfield, JP ; Brody, LC ; Buono, RJ ; Campbell, E ; Cascino, GD ; Catarino, CB ; Cavalleri, GL ; Cherny, SS ; Chinthapalli, K ; Coffey, AJ ; Compston, A ; Coppola, A ; Cossette, P ; Craig, JJ ; de Haan, G-J ; De Jonghe, P ; de Kovel, CGF ; Delanty, N ; Depondt, C ; Devinsky, O ; Dlugos, DJ ; Doherty, CP ; Elger, CE ; Eriksson, JG ; Ferraro, TN ; Feucht, M ; Francis, B ; Franke, A ; French, JA ; Freytag, S ; Gaus, V ; Geller, EB ; Gieger, C ; Glauser, T ; Glynn, S ; Goldstein, DB ; Gui, H ; Guo, Y ; Haas, KF ; Hakonarson, H ; Hallmann, K ; Haut, S ; Heinzen, EL ; Helbig, I ; Hengsbach, C ; Hjalgrim, H ; Iacomino, M ; Ingason, A ; Jamnadas-Khoda, J ; Johnson, MR ; Kalviainen, R ; Kantanen, A-M ; Kasperaviciute, D ; Trenite, DK-N ; Kirsch, HE ; Knowlton, RC ; Koeleman, BPC ; Krause, R ; Krenn, M ; Kunz, WS ; Kuzniecky, R ; Kwan, P ; Lal, D ; Lau, Y-L ; Lehesjoki, A-E ; Lerche, H ; Leu, C ; Lieb, W ; Lindhout, D ; Lo, WD ; Lopes-Cendes, I ; Lowenstein, DH ; Malovini, A ; Marson, AG ; Mayer, T ; McCormack, M ; Mills, JL ; Mirza, N ; Moerzinger, M ; Moller, RS ; Molloy, AM ; Muhle, H ; Newton, M ; Ng, P-W ; Noethen, MM ; Nuernberg, P ; O'Brien, TJ ; Oliver, KL ; Palotie, A ; Pangilinan, F ; Peter, S ; Petrovski, S ; Poduri, A ; Privitera, M ; Radtke, R ; Rau, S ; Reif, PS ; Reinthaler, EM ; Rosenow, F ; Sander, JW ; Sander, T ; Scattergood, T ; Schachter, SC ; Schankin, CJ ; Scheffer, IE ; Schmitz, B ; Schoch, S ; Sham, PC ; Shih, JJ ; Sills, GJ ; Sisodiya, SM ; Slattery, L ; Smith, A ; Smith, DF ; Smith, MC ; Smith, PE ; Sonsma, ACM ; Speed, D ; Sperling, MR ; Steinhoff, BJ ; Stephani, U ; Stevelink, R ; Strauch, K ; Striano, P ; Stroink, H ; Surges, R ; Tan, KM ; Thio, LL ; Thomas, GN ; Todaro, M ; Tozzi, R ; Vari, MS ; Vining, EPG ; Visscher, F ; von Spiczak, S ; Walley, NM ; Weber, YG ; Wei, Z ; Weisenberg, J ; Whelan, CD ; Widdess-Walsh, P ; Wolff, M ; Wolking, S ; Yang, W ; Zara, F ; Zimprich, F (NATURE PUBLISHING GROUP, 2018-12-10)
    The epilepsies affect around 65 million people worldwide and have a substantial missing heritability component. We report a genome-wide mega-analysis involving 15,212 individuals with epilepsy and 29,677 controls, which reveals 16 genome-wide significant loci, of which 11 are novel. Using various prioritization criteria, we pinpoint the 21 most likely epilepsy genes at these loci, with the majority in genetic generalized epilepsies. These genes have diverse biological functions, including coding for ion-channel subunits, transcription factors and a vitamin-B6 metabolism enzyme. Converging evidence shows that the common variants associated with epilepsy play a role in epigenetic regulation of gene expression in the brain. The results show an enrichment for monogenic epilepsy genes as well as known targets of antiepileptic drugs. Using SNP-based heritability analyses we disentangle both the unique and overlapping genetic basis to seven different epilepsy subtypes. Together, these findings provide leads for epilepsy therapies based on underlying pathophysiology.
  • Item
    No Preview Available
    Familial Mesial Temporal Lobe Epilepsy and the Borderland of Deja Vu
    Perucca, P ; Crompton, DE ; Bellows, ST ; McIntosh, AM ; Kalincik, T ; Newton, MR ; Vajda, FJE ; Scheffer, IE ; Kwan, P ; O'Brien, TJ ; Tan, KM ; Berkovic, SF (WILEY, 2017-08)
    OBJECTIVE: The cause of mesial temporal lobe epilepsy (MTLE) is often unknown. We ascertained to what extent newly diagnosed nonlesional MTLE actually represents familial MTLE (FMTLE). METHODS: We identified all consecutive patients presenting to the Austin Health First Seizure Clinic with MTLE and normal magnetic resonance imaging (MRI) or MRI evidence of hippocampal sclerosis over a 10-year period. Patients' first-degree relatives and pairwise age- and sex-matched controls underwent a comprehensive epilepsy interview. Each interview transcript was reviewed independently by 2 epileptologists, blinded to relative or control status. Reviewers classified each subject as follows: epilepsy, specifying if MTLE; manifestations suspicious for epilepsy; or unaffected. Physiological déjà vu was noted. RESULTS: Forty-four patients were included. At the Clinic, MTLE had been recognized to be familial in 2 patients only. Among 242 subjects interviewed, MTLE was diagnosed in 9 of 121 relatives versus 0 of 121 controls (p = 0.008). All affected relatives had seizures with intense déjà vu and accompanying features; 6 relatives had not been previously diagnosed. Déjà vu experiences that were suspicious, but not diagnostic, of MTLE occurred in 6 additional relatives versus none of the controls (p = 0.04). Physiological déjà vu was common, and did not differ significantly between relatives and controls. After completing the relatives' interviews, FMTLE was diagnosed in 8 of 44 patients (18.2%). INTERPRETATION: FMTLE accounts for almost one-fifth of newly diagnosed nonlesional MTLE, and it is largely unrecognized without direct questioning of relatives. Relatives of patients with MTLE may experience déjà vu phenomena that clinically lie in the "borderland" between epileptic seizures and physiological déjà vu. Ann Neurol 2017;82:166-176.